Pancreatic cancer organization adds new clinical trial sites


The Pancreatic Cancer Action Network (PanCAN), a non-profit organization aimed at fighting the disease, announced the opening of five additional Precision Promise adaptive clinical trial sites in the United States. The company has also launched an evaluation of an experimental pancreatic cancer treatment developed by Novartis.

Pancreatic cancer is considered a particularly difficult form of cancer, with an overall five-year survival rate of around 11%. Additionally, it is the third leading cause of cancer-related death in the United States.

According to PanCan, the Precision Promise program (launched in 2020) aims to advance the disease clinical development paradigm by providing a faster, more efficient and patient-centric approach to developing new treatment options and improving patient outcomes. pancreatic cancer. the patients.

The adaptive nature of Precision Promise allows us to regularly bring innovative experimental therapies to study against the current standard of care and we are excited to bring an experimental treatment option from Novartis into the fold.said Julie Fleshman, President and CEO of PanCAN.

PanCAN’s new clinical trial aims to evaluate the effectiveness of experimental pancreatic cancer therapies, including Novartis’ new drug combination. One of the goals is to work more efficiently by requiring fewer patients to understand if a potential new therapy works.

In Precision Promise, Novartis will test canakinumab (IL-1 beta inhibitor) and spartalizumab (PD-1 inhibitor) in combination with nab-paclitaxel and gemcitabine. The combination therapy will be made available to trial patients as each site fully activates the new protocol; interested patients are encouraged to check with their cancer care providers for availability at the nearest site.

The five new sites bring the total of PanCAN sites to 20 in the United States. At these sites, pancreatic cancer patients will be able to access the Precision Promise adaptive clinical trial. New designated sites include:

  • Harold C. Simmons Comprehensive Cancer Center (Dallas, TX)
  • University of Utah Huntsman Cancer Institute (Salt Lake City, Utah)
  • Mayo Clinic Cancer Center (Rochester, Minnesota)
  • Sylvester Comprehensive Cancer Center (Miami, Florida)
  • University of Michigan Rogel Cancer Center (Ann Arbor, Michigan)

Following the activation of these five additional institutions, PanCAN also plans to add 10 additional sites by early 2023, bringing Precision Promise to a total of 30 leading cancer centers nationwide and doubling the footprint of the test. A complete list of facilities currently open and actively recruiting patients is available at This list is updated as new sites are activated.

Pancreatic cancer patients deserve better treatment options“, Fleshman said. “We hope that by expanding Precision Promise’s access to more diverse populations and a total of thirty sites by early 2023, we will be able to deliver results that will improve patient outcomes in the future. .

During the Precision Promise New Site Selection Promise, PanCAN would have evaluated facilities with pancreatic cancer programs, reviewing facilities in different geographic regions that serve a diverse patient population in order to expand the trial access to generally underserved communities.


About Author

Comments are closed.